Log in

NASDAQ:SLDB - Solid Biosciences Stock Price, Forecast & News

$3.29
-0.06 (-1.79 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$3.26
Now: $3.29
$3.39
50-Day Range
$3.08
MA: $3.58
$4.43
52-Week Range
$2.75
Now: $3.29
$13.58
Volume281,868 shs
Average Volume273,627 shs
Market Capitalization$151.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45
Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLDB
CUSIPN/A
Phone617-337-4680

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.53 per share

Profitability

Net Income$-74,800,000.00

Miscellaneous

Employees111
Market Cap$151.31 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive SLDB News and Ratings via Email

Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.


Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc (NASDAQ:SLDB) released its earnings results on Wednesday, August, 14th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.81) by $0.05. View Solid Biosciences' Earnings History.

When is Solid Biosciences' next earnings date?

Solid Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Solid Biosciences.

What price target have analysts set for SLDB?

8 equities research analysts have issued twelve-month price targets for Solid Biosciences' shares. Their forecasts range from $2.00 to $22.00. On average, they anticipate Solid Biosciences' share price to reach $9.86 in the next year. This suggests a possible upside of 199.6% from the stock's current price. View Analyst Price Targets for Solid Biosciences.

What is the consensus analysts' recommendation for Solid Biosciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 2 sell ratings, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences.

Has Solid Biosciences been receiving favorable news coverage?

Media stories about SLDB stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Solid Biosciences earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Solid Biosciences.

Who are some of Solid Biosciences' key competitors?

What other stocks do shareholders of Solid Biosciences own?

Who are Solid Biosciences' key executives?

Solid Biosciences' management team includes the folowing people:
  • Dr. Andrey Juan Zarur, Co-Founder & Chairman of Directors (Age 48)
  • Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 45)
  • Mr. Pedro Alvaro Amorrortu, Chief Operating Officer (Age 47)
  • Dr. Carl Ashley Morris, Chief Scientific Officer (Age 49)
  • Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 48)

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers.

Who are Solid Biosciences' major shareholders?

Solid Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Boxer Capital LLC (2.24%), State Street Corp (0.76%), Geode Capital Management LLC (0.60%), Spark Investment Management LLC (0.30%), Charles Schwab Investment Management Inc. (0.19%) and Goldman Sachs Group Inc. (0.18%). Company insiders that own Solid Biosciences stock include Boxer Capital, Llc, Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur, Life Sciences Maste Perceptive, Matthew Bennett Arnold and Pedro Alvaro Amorrortu. View Institutional Ownership Trends for Solid Biosciences.

Which major investors are selling Solid Biosciences stock?

SLDB stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Matisse Capital, Citigroup Inc., Goldman Sachs Group Inc., Charles Schwab Investment Management Inc. and UBS Group AG. Company insiders that have sold Solid Biosciences company stock in the last year include Boxer Capital, Llc and Juan Andrey Zarur. View Insider Buying and Selling for Solid Biosciences.

Which major investors are buying Solid Biosciences stock?

SLDB stock was bought by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, State Street Corp, Geode Capital Management LLC, Renaissance Technologies LLC, Alambic Investment Management L.P., Tower Research Capital LLC TRC , Swiss National Bank and Credit Suisse AG. View Insider Buying and Selling for Solid Biosciences.

How do I buy shares of Solid Biosciences?

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $3.29.

How big of a company is Solid Biosciences?

Solid Biosciences has a market capitalization of $151.31 million. The company earns $-74,800,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Solid Biosciences employs 111 workers across the globe.View Additional Information About Solid Biosciences.

What is Solid Biosciences' official website?

The official website for Solid Biosciences is http://www.solidbio.com/.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680.


MarketBeat Community Rating for Solid Biosciences (NASDAQ SLDB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  391
MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote "Outperform" if you believe SLDB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel